» Articles » PMID: 33767996

Prognostic Signature of Immune Genes and Immune-Related LncRNAs in Neuroblastoma: A Study Based on GEO and TARGET Datasets

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Mar 26
PMID 33767996
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prognostic value of immune-related genes and lncRNAs in neuroblastoma has not been elucidated, especially in subgroups with different outcomes. This study aimed to explore immune-related prognostic signatures.

Materials And Methods: Immune-related prognostic genes and lncRNAs were identified by univariate Cox regression analysis in the training set. The top 20 C-index genes and 17 immune-related lncRNAs were included in prognostic model construction, and random forest and the Least Absolute Shrinkage and Selection Operator (LASSO) regression algorithms were employed to select features. The risk score model was constructed and assessed using the Kaplan-Meier plot and the receiver operating characteristic curve. Functional enrichment analysis of the immune-related lncRNAs was conducted using the STRING database.

Results: In GSE49710, five immune genes (CDK4, PIK3R1, THRA, MAP2K2, and ULBP2) were included in the risk score five genes (RS5_G) signature, and eleven immune-related lncRNAs (LINC00260, FAM13A1OS, AGPAT4-IT1, DUBR, MIAT, TSC22D1-AS1, DANCR, MIR137HG, ERC2-IT1, LINC01184, LINC00667) were brought into risk score LncRNAs (RS_Lnc) signature. Patients were divided into high/low-risk score groups by the median. Overall survival and event/progression-free survival time were shortened in patients with high scores, both in training and validation cohorts. The same results were found in subgroups. In grouping ability assessment, the area under the curves (AUCs) in distinguishing different groups ranged from 0.737 to 0.94, better in discriminating MYCN status and high risk in training cohort (higher than 0.9). Multivariate Cox analysis demonstrated that RS5_G and RS_Lnc were the independent risk factors for overall and event/progression-free survival (all p-values <0.001). Correlation analysis showed that RS5_G and RS_Lnc were negatively associated with aDC, CD8+ T cells, but positively correlated with Th2 cells. Functional enrichment analyzes demonstrated that immune-related lncRNAs are mainly enriched in cancer-related pathways and immune-related pathways.

Conclusion: We identified the immune-related prognostic signature RS5_G and RS_Lnc. The predicting and grouping ability is close to being even better than those reported in other studies, especially in subgroups. This study provided prognostic signatures that may help clinicians to choose optimal treatment strategies and showed a new insight for NB treatment. These results need further biological experiments and clinical validation.

Citing Articles

Fatty acid metabolism-related lncRNAs are potential biomarkers for survival prediction in clear cell renal cell carcinoma.

Zhang M, Yang B, Wang Z, Guo S Medicine (Baltimore). 2024; 103(8):e37207.

PMID: 38394500 PMC: 11309608. DOI: 10.1097/MD.0000000000037207.


A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer.

Zhu Y, Chen J, Zhou L, Zhang L, Liu Y, Zhuang Y J Oncol. 2023; 2022:7625138.

PMID: 37223641 PMC: 10202609. DOI: 10.1155/2022/7625138.


Mitochondria-associated gene expression perturbation predicts clinical outcomes and shows potential for targeted therapy in neuroblastoma.

Chai C, Chen Y, Luo Y, Zhang H, Ye Z, He X Front Pediatr. 2023; 11:1094926.

PMID: 37025299 PMC: 10070980. DOI: 10.3389/fped.2023.1094926.


Signature literature review reveals AHCY, DPYSL3, and NME1 as the most recurrent prognostic genes for neuroblastoma.

Chicco D, Sanavia T, Jurman G BioData Min. 2023; 16(1):7.

PMID: 36870971 PMC: 9985261. DOI: 10.1186/s13040-023-00325-1.


A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.

Tian X, Xiang B, Yu Y, Li Q, Zhang Z, Zhanghuang C Front Immunol. 2022; 13:999849.

PMID: 36211401 PMC: 9540510. DOI: 10.3389/fimmu.2022.999849.


References
1.
Wei J, Kuznetsov I, Zhang S, Song Y, Asgharzadeh S, Sindiri S . Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk -Not-Amplified Human Neuroblastoma. Clin Cancer Res. 2018; 24(22):5673-5684. PMC: 6504934. DOI: 10.1158/1078-0432.CCR-18-0599. View

2.
Meng X, Li H, Fang E, Feng J, Zhao X . Comparison of Stage 4 and Stage 4s Neuroblastoma Identifies Autophagy-Related Gene and LncRNA Signatures Associated With Prognosis. Front Oncol. 2020; 10:1411. PMC: 7466450. DOI: 10.3389/fonc.2020.01411. View

3.
Borriello L, Seeger R, Asgharzadeh S, DeClerck Y . More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett. 2015; 380(1):304-14. PMC: 5558454. DOI: 10.1016/j.canlet.2015.11.017. View

4.
Xiang Z, Huang X, Wang J, Zhang J, Ji J, Yan R . Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer. Front Pharmacol. 2018; 9:861. PMC: 6085474. DOI: 10.3389/fphar.2018.00861. View

5.
Jacquelot N, Pitt J, Enot D, Roberti M, Duong C, Rusakiewicz S . Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology. 2017; 6(8):e1299303. PMC: 5593705. DOI: 10.1080/2162402X.2017.1299303. View